Icariside II in NSCLC and COVID-19: Network pharmacology and molecular docking study.

Qing KongHuahe ZhuJing-Cheng DongBaojun Liu

Published in: The journal of gene medicine (2024)

IS may enhance the therapeutic efficacy of current clinical anti-inflammatory and anti-cancer therapy to benefit patients with NSCLC combined with COVID-19.

Keyphrases

molecular docking
coronavirus disease
sars cov
cancer therapy
small cell lung cancer
anti inflammatory
advanced non small cell lung cancer
molecular dynamics simulations
drug delivery
respiratory syndrome coronavirus
brain metastases
epidermal growth factor receptor